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Suicidal attempt with high dose long-acting methylphenidate: A case 
report
Yüksek doz metilfenidat ile intihar girişimi: Bir olgu sunumu
Duygu MURAT, Ayşe ARMAN
ABSTRACT
Stimulant medications are the most commonly used drugs for the 
treatment of attention-deficit hyperactivity disorder (ADHD). 
Reports of suicide attempts in ADHD cases with high dose long-
acting methylphenidate (MPH) are limited in the literature. In this 
case report, a 13-year-old boy who had attempted suicide by ingesting 
1350 mg long-acting MPH and 2 mg risperidon is discussed. While 
the patient did not   have life threatening symptoms, emergency 
medical intervention was necessary.
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ÖZET
Stimülanlar, dikkat eksikliği hiperaktivite bozukluğu (DEHB) 
tedavisinde yaygın olarak kullanılan ilaçlardır. Literatürde, DEHB 
olgularında uzun etkili metilfenidat ile intihar girişimi olgu 
sunumları sınırlı sayıdadır. Bu olgu sunumunda 1350 mg uzun 
etkili metilfenidat ve 2 mg risperidon ile intihar girişiminde bulunan 
13 yaşında erkek hasta tartışılmıştır. Hastada hayatı tehdit eden 
belirtiler olmamakla birlikte acil tıbbi müdahale gerekli olmuştur. 
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Introduction
The role of stimulants in treatment of children with attention-
deficit hyperactivity disorder (ADHD) was well-established 
by the 1970s. Since then, the database supporting the safety 
and efficacy of these stimulants has grown exponentially. 
Methylphenidate (MPH) increases dopamine and noradrenalin 
in synapses and extracellular spaces of dopaminergic neurons 
in the central nervous system (CNS) [1].  Both short and long-
acting MPH medications are widely used for the treatment of 
ADHD.  The safety and tolerability of long-acting stimulants 
are similar to those of short-acting stimulants, appear to have 
a somewhat lower risk of abuse and diversion, and may be 
associated with significant improvements in medication 
adherence [2, 3]. Short-acting medications, in contrast may 
allow for more flexibility with the dosing frequency, titration, 
and determining the drug tolerability and can be taken on an 
as-needed basis when coverage is needed for a few hours [4]. 
As the therapeutic uses of long-acting MPH preparations in 
children and adolescents with ADHD are increasing, so does 
the risk of unintentional and intentional overdoses due to 
abuse, misuse, and suicidal inclinations.  [4-6 ].
The intra-nasal and parenteral abuse of short-acting 
stimulants among teenagers has been reported in addition 
to mega dose ingestion for suicidal purposes among ADHD 
cases [7, 8]. Suicide attempts with long-acting MPH 
preparations have also been described in case reports [6, 9].
In the present report, we describe a suicide attempt 
involving a high dose (1350 mg) of long-acting MPH in a 
13-year-old boy.
Case Report
A 13-year-old boy, accompanied by his parents, was admitted 
to the emergency clinic approximately nine hours after 
ingesting 30 tablets of 27 mg long-acting MPH, 30 tablets of 
18 mg long-acting MPH, and 2 tablets of 1 mg risperidone.
Psychiatric history 
His mother had  had no medical problem during the 
pregnancy; there were no complications in the course of the 
perinatal period. His developmental history and intellectual 
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capacity were within normal limits. In his previous psychiatric 
history; his first visit to a child and adolescent psychiatrist 
was for hyperactivity when he was three years old. A solution 
of risperidone was prescribed between the ages of 3-7 for 
hyperactivity and impulsivity. He began to use MPH since 
age of seven.  He used the MPH prescriptions irregularly 
until  he was 10. Two years ago, he had a  cardiac arrest and 
was reanimated after a traffic accident. During the last 2 years 
he started to skip school, began to smoke and was frequently 
lying. His academic success decreased in school. His parents 
consulted a readmitted child and adolescent psychiatrist with 
these symptoms. Besides  ADHD, an additional diagnosis of 
a conduct disorder was also made and risperidone treatment 
was added to the MPH treatment. At the time of the suicide 
attempt, he was being treated with 27 mg of long-acting 
MPH daily with a moderate response. There was no history 
of any neurological disorder or substance abuse. There was 
no other concomitant medication used  for other medical 
purposes. Projective tests given by the psychologist revealed 
low frustration tolerance, motives of hostile dependency, and 
immature defences in response to aggression.
In his family history, his mother had a panic disorder 
diagnosis but nobody had been diagnosed as ADHD.  In 
follow-ups  he also presented depressive moods, consistently 
present for more than two weeks, therefore sertraline was 
also added to treatment. He reported increasing depressive 
symptoms over recent weeks and suicidal ideation over a 
few days in direct connection with conflicts in the family 
environment due to his school difficulties. There were no 
clues on a relation between the depressive symptoms and 
the stimulant medication. On the day on which he attempted 
suicide, he had skipped school. When he came home his 
mother threatened him by saying that she would tell his 
father. He was frightened of  his father, who would be angry 
with him and then attempted suicide. Before attempting 
suicide, he made a will. Then he took the pills in his room 
when he was alone. Thirty minutes later he started vomiting. 
He had palpitations and felt as if he was going to die. Then he 
decided to call his mother for help. 
Physical findings
During the physical evaluation in the emergency service, 
his vital signs were normal. His height and body weight  were 
176 cm and  54 kg., the heart rate was 98/min, the blood 
pressure was 110/70, O2 saturation was 98%. His respiration 
was spontaneous. Body temperature and laboratory findings 
were normal.  He was immediately taken to the reanimation 
department and was monitored. His stomach was irrigated 
through a nasogastric tube and then activated charcoal was 
administered  Antioxidant therapy (acetylcystein) was also 
given. Serum MPH concentrations were not measured due to 
lack of laboratory measures.
Psychopathological findings
When the boy presented to the hospital, his general 
appearance was moderately affected. He was somnolent and 
barely cooperative. 
During the first hour of the suicide attempt, his behavior 
changed abruptly and he mentioned that he was unable to 
control his movements. He showed moderate agitation and 
restlessness. He acted as though he was being vigilant.  There 
was increased salivation. He also complained about intense 
palpitations which were accompanied  by a feeling of sudden 
death. His mother described that he was nervous, logorrheic, 
and hyperkinetic at that time.
Clinical course
He was observed for two days in the intensive care unit. 
After all vital parameters were normal, he was discharged 
from the  hospital. The psychiatric follow-up was continued. 
MPH was prescribed again  for the impulsivity and risperidone 
medication is also added. 
Discussion
We have presented a 13-year-old boy, who after severe 
overdose of long-acting MPH, experienced the classical 
symptoms of a sympathomimetic syndrome with 
cardiovascular symptoms and acute neurological toxicity. 
MPH, a piperidine-derived CNS stimulant, is widely used for 
the management of ADHD [10]. Side effects of MPH include 
nervousness, headache, insomnia, anorexia, and tachycardia 
which increase linearly with dose. Clinical manifestations 
of a drug overdose include agitation, hallucination, 
psychosis, lethargy, seizures, tachycardia, dysrhythmias, 
hypertension, and hyperthermia [11]. In all stimulant 
groups, clinical findings consist mainly of the symptoms 
and signs of sympathetic nervous system stimulation, 
such as palpitation, sinus tachycardia, hypertension and 
mydriasis [2,3]. Other frequently observed clinical findings 
include agitation, disorientation and anxiety [12]. In cases 
of severe intoxication, there may also be hyperthermia and 
rhabdomyolysis.
Data from the US Poison Centre have shown that 
in children single exposures up to 80 mg MPH are 
well-tolerated [13]. Only  few data about intoxications 
with higher doses exit, and the toxic ranges of blood 
concentrations of extended release MPH formulations in 
children and adolescents have  not been evaluated [2,3]. 
Patients who ingest more than 4 mg/kg or 120 mg of an intact 
modified-release formulation of MPH should be referred 
to an emergency department for oral exposures. Emesis 
induction is strictly contraindicated  and  administration of 
charcoal activated before reaching the hospital,  if available, 
should only be carried out by health professionals after 
controlling other contraindications [5, 11]. Benzodiazepines 
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can be administered if agitation, dystonia, or convulsions 
are present. Standard advanced cardiac life support (ACLS) 
measures should be administered if respiratory arrest, cardiac 
dysrhythmias, or cardiac arrest is present [5].
A case report has described acute myocardial infarction 
in  an adolescent one week after restarting a daily 20 mg 
prescription of mixed amphetamine salts [14]. Cardiac 
arrest occurred in another adolescent who was taking 
MPH for ADHD and who had previously had a normal 
baseline echocardiogram [15]. There have also been case 
reports of acute myocardial infarction in young patients 
who took therapeutic doses of MPH with concomitant 
use of other medications (bupropion, erythromycin and 
pseudoephedrine) [16]. Two case reports have described 
serious cardiomyopathies in young adult patients treated 
with MPH [17]. One account of a 28 year-old girl who had 
ingested 90 mg MPH with  suicidal intent  was published in 
2010, describing an acute coronary syndrome secondary to 
the MPH overdose [8].  MPH increases adrenergic action in 
the CNS as well as in the circulatory system and  is believed 
to be cardio toxic over time possibly producing a dilated 
cardiomyopathy  as the end result [18]. 
Two suicide attempts with long-acting MPH, a 14-year 
girl (1134 mg) (6) and 17-year-old girl (270 mg) (9) have 
been reported. Our patient ingested 1350 mg of MPH along 
with 2 mg risperidone. This is the highest dose of long-acting 
MPH ingested with suicidal intent our patient had no signs 
of cardiac toxicity, hallucinations, agitation, hyperthermia or 
rhabdomyolysis. A possible explanation for the good clinical 
outcome in our patient may be  the spontaneous vomiting 
after 30 minutes of the high-dose MPH ingestion; this may 
have been protective for this patient. Hyperemesis and 
vomiting are reported in one tenth of MPH overdose cases in 
a study of Hill’s et al. [19]. In our patient the vomiting may 
explain the reduced side effects of MPH, no matter whether 
the vomiting was due to a gastric irritation, or to higher 
levels of CNS dopamine.  The cause of vomiting  needs to 
be investigated in depth  in future studies.
As a conclusion, exposure to a large overdose of 
long-acting MPH exhibited minor symptoms of acute 
sympathomimetic toxicity but no life-threatening symptoms 
in this patient. Thus, this case report suggests that patients 
intoxicated with high dose long-acting MPH formulations 
might recover without sequelae in emergency settings. While 
long-acting stimulants offer lower risk of abuse, their greater 
availability increases the likelihood of ingestion for suicidal 
ends. Education of clinicians and families to be aware of this 
risk should reduce the frequency of this unwanted result of 
drug treatment.
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